SEC Form 4Coverage since May 20, 2026
$INM insider trading
Over the last 12 months, InMed Pharmaceuticals insiders reported 4 buys totaling $435K and no sales across SEC Form 4 filings.
- Bought · 12m
- $435K 4 events
- Sold · 12m
- — 0 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $INM · 12Mvia TradingView
Top insiders · 12m
Vivo Opportunity, LLC—3× · $434K
ADAR1 Capital Management, LLC—1× · $2K
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Vivo Opportunity, LLC10% | ▲ Buy | 20,546 | $1.55 | $32K | +37.7% | 6 tranches · indirect |
| Jul 15, 2026 | ADAR1 Capital Management, LLC10% | ▲ Buy | 1,000 | $1.56 | $2K | +0.1% | indirect |
| Jul 2, 2026 | Vivo Opportunity, LLC10% | ▲ Buy | 6,551 | $1.55 | $10K | +9.8% | 6 tranches · indirect |
| Jun 8, 2026 | Vivo Opportunity, LLC10% | ▲ Buy | 249,227 | $1.57 | $392K | — | 18 tranches · indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $INM feed.